A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

StatusRecruiting
PhasePhase 4
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Site details revised at 9 of 36 sitesv12
  2. Re-verified, no change to tracked fieldsv11
  3. Site contacts updated at 4 of 36 sitesv10
  4. Site details revised at 2 of 36 sitesv9
  5. Study sites: 35 to 36v8
Show 6 earlier versionsHide 6 earlier versions
  1. Study sites: 36 to 35
    • Secondary endpoints: details revised at 1 of 1 entry
    v7
  2. Primary endpoint revised
    • Eligibility criteria shortened, about 38 words
    • Site details revised at 15 of 36 sites
    v6
  3. Study sites revised (36)v5
  4. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of May 2025 to May 20, 2025
    • Site details revised at 36 of 36 sites
    v4
  5. Study sites: 35 to 36v3
  6. Study sites: 1 to 35
    • Start date: Apr 2025 to May 2025
    v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Study J2N-MC-JZ01 (JZ01) is an individual-study appendix (ISA) under master protocol J2N-MC-JZNY, and represents participants from the completed originator study, clinical study LOXO-BTK-18001/J2N-OX-JZNA. Participants in the originator study will have the opportunity to continue their assigned study intervention or continue their follow-up visits by transitioning to this study. This study will evaluate the long-term safety and efficacy of pirtobrutinib.
Trial Details
NCT Number NCT06876662
Lead Sponsor Eli Lilly and Company
Conditions
(from sponsor)		 Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma
Related terms Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Non-Hodgkin
Enrollment 279 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov